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Objective: To compare persistence with valsartan and enalapril in daily practice.
Methods: The PHARMO Record Linkage System includes various data registries including 
drug dispensing and hospitalizations for  2 million subjects in the Netherlands. Patients newly 
treated with valsartan or enalapril in the period of 1999–2002 were selected. Persistence was 
calculated by summing up the number of days of continuous treatment. Patients who remained 
on therapy with valsartan or enalapril for 12 or 24 months were deﬁ  ned as persistent at 1 or 
2 years, respectively.
Results: 3364 patients received valsartan and 9103 patients received enalapril. About 62% of 
patients treated with valsartan and 55% of patients treated with enalapril remained on therapy 
at 12 months after the initial dispensing, while 48% of patients treated with valsartan and 43% 
of patients treated with enalapril were persistent at 24 months. Patients treated with valsartan 
were about 20% more likely to stay on treatment than patients treated with enalapril (1 year 
RRadj: 1.23, 95% CI: 1.16–1.32; 2 years RRadj: 1.16, 95% CI: 1.11–1.23).
Conclusions: Real-life persistence is higher with valsartan than with enalapril. The results 
of this and other studies on persistence in daily practice should be taken into account when 
deciding upon drug treatment for hypertension.
Keywords: persistence, antihypertensive, valsartan, enalapril, angiotensin-converting enzyme 
inhibitors, angiotensin-2-receptor blockers
Introduction
Hypertension is a major risk factor for vascular disease and effective treatment with 
antihypertensive drugs has been shown to reduce both cardiovascular and cerebrovas-
cular events (Gueyfﬁ  er et al 1997). However, at least three quarters of antihypertensive 
patients fail to achieve optimal blood pressure control despite of treatment and accord-
ing to the ﬁ  ndings of the World Health Organization, poor adherence to treatment is an 
important cause of uncontrolled blood pressure (WHO 2003). Several methods have 
been developed to measure adherence using drug dispensing information from large 
pharmacy databases, including measurements of reﬁ  ll compliance and persistence 
(Steiner and Prochazka 1997; Catalan and LeLorier 2000; Dezii 2001; Halpern et al 
2006). Between 50% and 70% of patients with treated hypertension adhere to antihy-
pertensive medication, irrespective of the method used. Several observational studies 
have demonstrated that the choice of the initial antihypertensive drug class has an 
important impact on persistence with the treatment regimen (Caro et al 1999b; Hasford 
et al 2002; Marentette et al 2002; Morgan and Yan 2004; Erkens et al 2005; Koylan 
et al 2005; Mazzaglia et al 2005). Most studies showed highest persistence rates with 
angiotensin-2-receptor blockers (ARBs), followed by angiotensin converting enzyme 
inhibitors (ACE inhibitors) (Marentette et al 2002; Bourgault et al 2005; Erkens et al 
2005; Koylan et al 2005; Gerth 2002). Lowest persistence rates were observed for 
diuretics (Caro et al 1999b; Hasford et al 2002; Bourgault et al 2005; Chou et al 2005). Vascular Health and Risk Management 2007:3(6) 1040
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Important reasons for non-adherence with antihypertensive 
medication include patient demographic factors (such as age 
and gender), low conﬁ  dence in the physician, perceived or 
experienced adverse effects of drugs, notion of hypertension 
as an intermittent condition, and complex dosing regimens 
(Svensson et al 2000; Mancia et al 2003; Ross et al 2004; 
Breekveldt-Postma and Herings 2005).
Although several studies have been published on 
persistence and compliance with ARBs compared to other 
groups of antihypertensive drugs, very little is known 
about the differences that exist between individual drugs. 
Wogen et al reported higher compliance and persistence 
rates with valsartan (ARB) than with lisinopril (ACE 
inhibitor) and amlodipine (calcium-channel blocker, CCB) 
after 1 year in patients that were new on the speciﬁ  c anti-
hypertensive drug (Wogen et al 2003). In the Netherlands, 
use of ARBs and ACE inhibitors are recommended for 
high-risk hypertensive patients with similar compelling 
indications, such as diabetes mellitus, chronic kidney dis-
ease, heart failure, and post-myocardial infarction. These 
recommendations are in line with international guidelines 
(ESH 2003).
The objective of this study was to compare persistence 
with the ARB valsartan and the ACE inhibitor enalapril in 
daily practice during the ﬁ  rst two years of treatment in hyper-
tensive patients that were new on the index drug (valsartan 
or enalapril). Enalapril was selected as a comparator for 
valsartan, because it is the most frequently dispensed ACE 
inhibitor in the Netherlands.
Methods
Setting
Data were obtained from the PHARMO medical record 
linkage system (PHARMO RLS) in the Netherlands. The 
PHARMO RLS includes the demographic details and com-
plete medication history of more than 2 million patients, 
further linked to hospital admission records as well as sev-
eral other health registries, including pathology and clinical 
laboratory ﬁ  ndings (Herings 1993). Computerized drug dis-
pensing histories contain Anatomical Therapeutic Chemical 
(ATC) codes, the date of medication dispensing, prescriber 
information, prescribed dose of the drug, dispensed quantity, 
cost and duration of use. Hospital admission register com-
prises all hospital admissions in the Netherlands, including 
detailed information on the primary and secondary discharge 
diagnoses, diagnostic, surgical and treatment procedures, 
type and frequency of consultations with medical specialists 
and dates of hospital admission and discharge. All diagnoses 
are coded according to the International Classiﬁ  cation of 
Diseases, 9th edition (ICD-9-CM).
Study cohort
The study population included all patients with at least one 
dispensing of valsartan (ATC code: C09CA03) or enalapril 
(ATC code: C09AA02) in the PHARMO community phar-
macy database between 1 January 1999 and 31 December 
2002. Only products with one active substance were included 
in the selection, patients starting a ﬁ  xed combination therapy 
including valsartan or enalapril were excluded. The date of 
the ﬁ  rst dispensing was deﬁ  ned as the index date and the 
drug prescribed was deﬁ  ned as the index drug. Patients were 
eligible for inclusion if they had a history of registration 
in PHARMO RLS of at least 12 months before the index 
date and a follow-up of at least 24 months. Patients did not 
use the index drug for at least 1 year before the index date 
and had at least 1 additional dispensing of the index drug 
within 60 days after the end date of the initial prescription to 
exclude patients not using the index drug for the treatment 
of chronic hypertension. For the same reason, patients who 
used nitrates (ATC code: C01DA) or alpha-blockers (ATC 
code: C02CA) during the 12-month period prior to the index 
date or during the ﬁ  rst treatment episode were excluded. The 
patients included in the ﬁ  nal study cohort were new users of 
the index drug, but not necessarily naïve to antihypertensive 
drug treatment.
Persistence
Medication persistence with the index drug was studied for 
12 and 24 months, respectively (Halpern et al 2006). For 
each patient, the duration of use of each dispensing of the 
index drug was calculated by dividing the number of units 
dispensed by the prescribed number of units to be used per 
day as recorded in the pharmacies. All dispensings were 
subsequently converted into treatment episodes. A treatment 
episode was deﬁ  ned as a period of time in which a continuous 
speciﬁ  c pharmacotherapeutic treatment took place and was 
measured as the time span between the starting date of the 
ﬁ  rst dispensing until the expiry date of the ﬁ  nal dispensing 
including the permissible gap. In case of an interruption of 
60 days or less between 2 dispensings, the treatment episode was 
considered uninterrupted. Patients were considered to discon-
tinue treatment if the gap between the end of the dispensed 
supply of one dispensing and the start of the next dispens-
ing was more than 60 days. Patients may have had multiple 
treatment episodes in their follow-up period, but only the ﬁ  rst 
treatment episode was used to calculate persistence with the Vascular Health and Risk Management 2007:3(6) 1041
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index drug. For patients continuously treated during the 12 
months or 24 months of follow-up, the duration of treatment 
was censored at one or two years, respectively (Catalan and 
LeLorier 2000). In addition to the persistence with the index 
drug only, persistence was calculated based on the use of any 
antihypertensive drug during the ﬁ  rst year after the index 
date. Persistence ended at discontinuation of all antihyper-
tensive drugs after start of the index drug.
Possible confounders
Other factors that may inﬂ  uence persistence were determined 
including age, gender, ﬁ  rst prescriber and year of start at 
the index date. Use of other antihypertensives (ATC-codes: 
C02, C03, C07, C08, C09A, C09B, C09C, C09D) was 
assessed in the period of 1 year prior to the index date and 
during the ﬁ  rst treatment episode, whereas hospitalization 
for hypertension (ICD-9-CM: 401–405) was determined 
in the 1-year period prior to the index date. Cardiovascular 
co-morbidity (yes/no) was assessed in the 1-year period prior 
and during the ﬁ  rst treatment episode based on drug use and 
hospital admission. Speciﬁ  c drugs that were determined 
included antithrombotics (ATC-code: B01), lipid lowering 
drugs (ATC-code: C10), antidiabetics (ATC-code: A10) 
and other cardiovascular drugs (ATC-codes: C01, C04 and 
C05). Cardiovascular hospitalizations included heart failure 
(ICD-9-CM: 428), ischemic heart diseases (ICD-9-CM: 
410–414), cerebrovascular diseases (ICD-9-CM: 430–438), 
other cardiovascular events (ICD-9-CM: 390–459 excluding 
the before mentioned hospitalizations), diabetes (ICD-9-CM: 
250), renal failure (ICD-9-CM: 584–586), and other renal 
events (ICD-9-CM: 580–589 excluding the before-mentioned 
hospitalizations). Hospitalization for any non-cardiovascular 
co-morbidity (yes/no) was assessed in the 1-year period prior 
to the index date.
Statistical analysis
Logistic regression analysis was performed to compare 
baseline characteristics between users of valsartan and 
users of enalapril. Survival functions describing persistence 
with valsartan and enalapril over time were computed using 
Kaplan Meier survival analyses. Sensitivity analyses were 
performed using a 30-day gap and 90-day gap, respectively. 
Crude and multivariate analyses to identify the effect of anti-
hypertensive drug on persistence were conducted using Cox’s 
proportional hazard analyses. Factors univariately associated 
with persistence were included as potential confounders in 
the adjusted analyses. Statistical signiﬁ  cance was deﬁ  ned at 
an alpha level of 0.05. All data were analyzed using SAS 
programs organized within SAS Enterprise Guide version 2.0 
(SAS Institute Inc., Cary, NC, USA) and conducted under 
UNIX using SAS version 8.2.
Results
A total of 3364 patients treated with valsartan and 9103 
patients treated with enalapril were included in the study 
cohort of which 8077 (65%) patients had been treated with 
other antihypertensive drugs during the 12-month period 
prior to and preceding the index date.
The signiﬁ  cant differences in patient characteristics 
between the two treatment groups are described below. 
These characteristics were included as possible confounders 
in the multivariate analyses when studying persistence with 
valsartan and enalapril treatment. Among patients starting 
valsartan treatment there were less patients in the oldest ( 80 
years of age) and youngest age category ( 40 years of age) 
than among patients starting enalapril treatment (Table 1). 
The proportion of females was higher among patients taking 
valsartan compared to enalapril. The proportion of patients 
who had been treated with an ACE inhibitor, ARB, or CCB 
blocker during the one-year period prior to the index date was 
higher among patients starting valsartan than among patients 
starting enalapril, whereas the proportion of patients who 
had used a diuretic during the preceding year was higher for 
patients starting enalapril than for patients starting valsartan. 
A history of a lipid-lowering drug use was more common 
within valsartan than enalapril users whereas the use of 
antidiabetic agents was more common for patients starting 
enalapril. A previous hospitalization for any renal event was 
more common among enalapril than valsartan users.
61.6% of patients starting valsartan and 55.0% of patients 
starting enalapril remained on therapy with the index drug 
at one year after the initial dispensing. Sensitivity analyses 
for 1-year persistence showed that about 50% of patients 
starting valsartan and 45% of patients starting enalapril 
remained on therapy when a 30-day gap was used and about 
65% of patients starting valsartan and 60% of patients starting 
enalapril remained on therapy when a 90 day gap was used. 
At two years after start, 47.8% of patients starting valsartan 
and 43.0% of patients starting enalapril were still using the 
index drug. Patients starting valsartan were 20% (1.2 times) 
more likely to persist with the initial therapy than patients 
starting enalapril at 1 and 2 years, after adjustment for 
differences in patient characteristics (RR1year: 1.23, 95% CI: 
1.16–1.32; RR2 years: 1.16, 95% CI: 1.11–1.23) (Table 2 and 
Figure 1). Factors adjusted for and associated with increased 
persistence in the multivariate analyses were higher age, Vascular Health and Risk Management 2007:3(6) 1042
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male gender, specialist as prescriber, concomitant use of 
other antihypertensive drugs, and previous use of concurrent 
cardiovascular medication as well as previous cardiovascular 
hospitalizations (data not shown). The lower persistence with 
enalapril was mainly due to higher rate of discontinuation 
of the drug during the ﬁ  rst year of treatment in the enalapril 
group (45%) than in the valsartan group (38%) (Figure 1).
When persistence was assessed based on the use of the 
index drug or any other antihypertensive drug during the ﬁ  rst 
year of follow-up, about 90% of the patients starting valsartan 
or enalapril were still on antihypertensive drug treatment after 
one year while 87% of patients starting valsartan and 84% 
of patients starting enalapril were on antihypertensive drug 
treatment after 2 years (Figure 2). No differences in overall 
persistence were observed between the treatment groups 
when using this deﬁ  nition (data not shown).
Discussion
This study indicates that patients starting valsartan treat-
ment are more persistent with their initial drug than patients 
starting enalapril treatment, after adjusting for differences in 
patient characteristics. Patients starting valsartan were 20% 
(1.2 times) more likely to persist with the initial therapy at one 
and two years after the start of the index drug than patients 
starting enalapril. Most patients (86%) were persistent with 
antihypertensive drug treatment after stopping the index drug 
but had switched either to another drug or to a combination 
of antihypertensive drugs.
The results of our study are in line with one other publica-
tion on persistence with individual antihypertensive drugs 
(Wogen et al 2003). The study by Wogen et al reported an 
increased persistence with valsartan compared to lisinopril 
(another representative of the ACE inhibitor class) in a usual-
care setting of a managed care organization in the US. In 
their study, 63% of patients treated with valsartan and 50% 
of patients treated with lisinopril stayed on the initial 
therapy at one year. No information was available on 2-year 
persistence rates. Enhanced persistence with ARBs in general 
compared with ACE inhibitors was also found in several 
studies on persistence with antihypertensive drug classes 
(Gerth 2002; Marentette et al 2002; Wogen et al 2003; 
Bourgault et al 2005; Erkens et al 2005).
Lower persistence with enalapril was mainly due to a 
higher rate of discontinuation of this drug during the ﬁ  rst 
year of treatment and may be related to the characteristic 
side-effects of ACE inhibitors, mainly cough (Dicpinigaitis 
2006). However, the actual reasons for drug discontinuation 
remain to be investigated in primary research on patients’ 
behavior. Factors related to cardiovascular disease severity, 
such as previous use of concurrent cardiovascular drugs and 
concomitant use of antihypertensive drugs were associated 
with greater persistence, as previously observed by others 
(Caro et al 1999a; Breekveldt-Postma and Herings 2005; 
Erkens et al 2005; Perreault et al 2005). These data indicate 
that patients with more severe hypertension are more likely 
to take medications as directed because of the perceived need 
to treat their condition effectively.
The indications of use between ACE inhibitors and 
ARBs are not fully overlapping; both drugs are indicated 
for essential hypertension while speciﬁ  c indications for ACE 
inhibitors are chronic kidney disease and diabetes mellitus. 
ACE inhibitors are also used post-myocardial infarction and 
Table 1 General characteristics of patients starting valsartan or 
enalapril therapy
   Valsartan     Enalapril 
Characteristic N  %  N  %
Total 3364  100.0  9103  100.0
Gender
 Female  (Ref.)  1939  57.6  4951  54.4
 Male  1425  42.4a 4152  45.6
Age (years)
 0–39  180  5.4a 609  6.7
 40–64  (Ref.)  1832  54.5  4695  51.6
 65–79    1174  34.9  3124  34.3
   80 178  5.3a 675  7.4
 Mean  ± sd  60.5 ± 12.6    60.4 ± 13.9
Prescriber
 GP  (Ref.)  2613  77.7  6955  76.4
 Specialist  751  22.3  2148  23.6
Previous use of antihypertensive drugs
 Any  AHT  2249  66.9a 5828  64.0
 Diuretic  862  25.6a 3126  34.3
 Beta-blocker  1253  37.2  3529  38.8
 ACE  781  23.2a 740  8.1
 ARB  284  8.4a 227  2.5
 CCB  483  14.4a 1011  11.1
 Miscellaneous  49  1.5a 89  1.0
Previous use of other cardiovascular drugs
  Any CV drug  1277  38.0a 3775  41.5
 Antithrombotic  682  20.3  1720  18.9
 Lipid-lowering  drug  557  16.6a 1153  12.7
 Antidiabetic  agent 332  9.9a 1829  20.1
 Other  273  8.1a 599  6.6
Previous hospitalizations
 CV  event  162  4.8  437  4.8
 Diabetes  4  0.1  28  0.3
 Renal  event  6  0.2a 50  0.5
 Other  378  11.2  1037  11.4
aStatistically signiﬁ  cant for valsartan vs enalapril p   0.05. 
Abbreviations: ACE, angiotensin converting enzyme inhibitor; AHT, antihy-
pertensive; ARB, angiotensin-2-receptor blocker; CCB, calcium-channel blocker; 
CV, cardiovascular; GP, general practitioner; Ref, reference group. Vascular Health and Risk Management 2007:3(6) 1043
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in patients with heart failure. ARBs are reserved for the latter 
patients in case they do not tolerate ACE inhibitors. These dif-
ferences in indication of use were also observed when com-
paring baseline characteristics of valsartan and enalapril. The 
differences in indication of use do not explain the observed 
differences in persistence of use as the adjusted risk estimate 
was similar to the crude risk estimate. Antihypertensives 
should be used chronically for all indications. In addition, as 
ACE inhibitors are more often used in high-risk patients, it 
is assumed that these patients would be more persistent with 
their therapy than low-risk patients which would result in 
an underestimation of the difference in persistence between 
valsartan and enalapril when not fully adjusted for.
Although we included a number of known confounders 
in our analyses, there may be other confounding factors 
for which we did not have information available, such as 
patient perceptions and channeling of (higher propensity to 
prescribe) the study drugs to different groups of patients, 
which may have inﬂ  uenced the results. We did not have 
information on socio-economic factors; however, both drugs 
are fully reimbursed in The Netherlands. It is possible that 
valsartan is being prescribed to patients who have not been 
persistent with other antihypertensive drugs. Therefore, the 
differences in persistence may partly be explained by residual 
confounding. On the other hand, no statistically signiﬁ  cant 
differences were observed in persistence rates based on the 
use of the index drug or any other antihypertensive drug 
between patients starting valsartan and patients starting enala-
pril. This strengthens the assumption that lower persistence 
with enalapril is related to differences between the individual 
drugs rather than differences in other factors associated with 
persistence between the two groups of patients. We cannot 
exclude that there may remain differences in persistence 
between valsartan and enalapril that relate to differences 
in indication of use, but we minimized possible differences 
in indication of use by excluding patients using nitrates pre-
viously or concomitantly with AHT treatment, by excluding 
patients with a single prescription of the index drug, and by 
concentrating on therapies that are representatives of drug 
classes recommended for the treatment of hypertension 
among patients with similar compelling indications.
In conclusion, patients treated with valsartan had higher 
persistence with their initial treatment compared to patients 
treated with enalapril. Lower real-life persistence may affect 
long-term health outcomes and lead to increased cost of ill-
ness. It is therefore important to take into account the results 
of this and other studies on persistence in daily practice when 
deciding upon drug treatment for hypertension.
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Table 2 Medication persistence with valsartan and enalapril
Persistence  N  At 1 year after the index date        At 2 years after the index date               
    Persistent (%)  RR  95% CI  RRb  95% CI  Persistent (%)  RR  95% CI  RRb 95%  CI
Enalapril  9103 55.0  1.00 Reference  1.00 Reference 43.0  1.00 Reference  1.00 Reference
Valsartan 3364  61.6  1.22a 1.15–1.30  1.23a 1.16–1.32  47.8  1.16a 1.10–1.22  1.16a 1.11–1.23
aStatistically signiﬁ  cant p   0.05.
bAdjusted for gender, age, type of prescriber, current and previous use of antihypertensive drugs, previous cardiovascular co-medication, and previous cardiovascular 
hospitalizations.
Figure 1 Medication persistence with valsartan and enalapril treatment in the ﬁ  rst 
2 years after the index date (adjusted curves based on the Cox proportional hazard 
analysis). Percentage of patients still using index drug at (a) 1 year after the index 
date: 61.6% for valsartan and 55.0% for enalapril and (b) 2 years after the index date: 
47.8% for valsartan and 43.0% for enalapril (p   0.05).
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